Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Neuberg Centre For Genomic Medicine, |
RCV003448837 | SCV004176610 | uncertain significance | Hypertrophic cardiomyopathy 1 | 2023-03-01 | criteria provided, single submitter | clinical testing | The missense c.1420A>G (p.Met474Val) variant in MYLK2 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. The p.Met474Val variant is novel (not in any individuals) in both gnomAD Exomes and 1000 Genomes databases. This variant has not been reported to the ClinVar database. The amino acid change p.Met474Val in MYLK2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Met at position 474 is changed to a Val changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as a Variant of Uncertain Significance (VUS). |
Ambry Genetics | RCV004827966 | SCV005451574 | uncertain significance | not specified | 2024-08-12 | criteria provided, single submitter | clinical testing | The c.1420A>G (p.M474V) alteration is located in exon 10 (coding exon 9) of the MYLK2 gene. This alteration results from a A to G substitution at nucleotide position 1420, causing the methionine (M) at amino acid position 474 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |